Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc

YUFEANG ZUO†, DONGYAN YANG†, YIN YU†, MEI XIANG, HAIWEN LI, JUN YANG, JINGJING LI, DANXIAN JIANG, HECHAO ZHOU, ZUMIN XU and ZHONGHUA YU

Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524000, P.R. China

Received December 8, 2016; Accepted August 11, 2017

DOI: 10.3892/mmr.2017.8301

Abstract. Lung cancer is a leading cause of cancer-associated mortality worldwide. The cisplatin (DDP)-based chemotherapy remains the foundation of treatment for the majority of patients affected by advanced non-small cell lung cancer (NSCLC). However, DDP-resistance limits the clinical utility of this drug in patients with advanced NSCLC. The aim of the present study was to investigate the inhibitory effect of niclosamide on human lung cancer cell growth and to investigate the possible underlying mechanism. The effects of niclosamide on the proliferation of human lung adenocarcinoma (A549) and DDP-resistant (CR) human lung adenocarcinoma (A549/DDP) cells were examined by Cell Counting kit-8 assay. The expression levels of cisplatin-resistant-associated molecules (lung resistance-related protein and c-myc) following niclosamide treatment in A549/DDP cells were evaluated by western blot analysis. The results indicated that niclosamide in combination with DDP demonstrated a synergistic effect in A549/DDP cells and directly induced apoptosis, which may be associated with caspase-3 activation. Furthermore, niclosamide decreased the expression level of c-myc protein, which may influence DDP sensitivity of A549/DDP cells. Thus, the present study indicates that niclosamide combined with DDP exerts a synergistic effect in cisplatin-resistant lung cancer cells and may present as a promising drug candidate in lung cancer therapy.

Introduction

Lung cancer remains one of the most common types of fatal malignancy. Non-small cell lung cancer (NSCLC), characterized by its high incidence, is the leading cause of cancer-associated mortality worldwide (1). NSCLC accounts for approximately 80-85% of all lung cancer cases (2) and the majority of patients are diagnosed with local advanced or metastatic disease (3). Although the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommended as first-line treatment for patients whose tumors harbor activating EGFR mutations (4), platinum-based, double-agent chemotherapy represents the standard of care for unselected patients with advanced NSCLC (5). Cisplatin (DDP) is a commonly used drug with a high curative effect on lung cancer (6). However, in chemotherapy-treated NSCLC, the duration of response is relatively short due to primary or acquired resistance to chemotherapy (7,8). Therefore, it is considered to be urgent to improve the efficacy of DDP-based chemotherapy and to develop novel treatment strategies to overcome DDP resistance for advanced NSCLC.

Niclosamide, a teniacide in the anthelmintic family, which is particularly effective against cestodes, has been approved for use in humans for many years (9). A recent study reported that niclosamide was a multi-functional agent, performing anti-obesity (10), anti-diabetic (11), anti-viral (12,13) and anti-sclerotic (14) activities. Additionally, niclosamide has been identified as a potent anticancer agent using various high-throughput screening assays (15). Niclosamide inhibits the Wnt/β-catenin, mammalian target of rapamycin complex 1, signal transducer and activator of transcription 3 (STAT3), nuclear factor-kB and Notch signaling pathways, and targets mitochondria in cancer cells to induce cell cycle arrest, growth inhibition and apoptosis. A host of studies have established the anticancer activities of niclosamide in in vitro and in vivo models. Furthermore, Li et al (16) identified that niclosamide overcame acquired resistance to erlotinib via suppression of STAT3 in NSCLC. Liu et al (17) demonstrated that niclosamide alone or in combination with DDP significantly inhibited MDA-MB-231/DDP-sensitive (CS) and MDA-MB-231-DDP-resistant (CR) cell
proliferation in vitro. However, the effect of niclosamide on cisplatin-resistant human lung cancer cells remains unknown.

In the present study, whether niclosamide could enhance the cytotoxic effects of DDP in cisplatin-resistant A549/DDP lung cancer cells was investigated, and the underlying mechanisms were evaluated further.

Materials and methods

Cell culture. Human A549 lung carcinoma cells and cisplatin-resistant human A549/DDP lung carcinoma cells were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in GibcoRPMI-1640 medium (Thermo Fisher Scientific, Inc, Waltham, MA, USA), supplemented with 10% (v/v) dialyzed heat-inactivated bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in 5% CO₂.

Cell viability assay. Cell viability was determined using the Cell Counting kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). CCK-8 allows very convenient assays by utilizing Dojindo's highly water-soluble tetrazolium salt. WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] produces a water-soluble formazan dye upon reduction in the presence of an electron carrier. CCK-8 allows sensitive colorimetric assays for the determination of the number of viable cells in cell proliferation and cytotoxicity assays. WST-8 is reduced by dehydrogenases in cells to give an orange colored product (formazan), which is soluble in the tissue culture medium. The quantity of formazan dye generated by the activity of dehydrogenases in cells is directly proportional to the number of living cells. Briefly, cells in the early log phase were trypsinized and plated in 96-well plates at a density of 5x10⁴ cells per well. Cells were treated with various concentrations of niclosamide (Sigma-Aldrich; Merck KGa, Darmstadt, Germany) and DDP (Haosen Medicine Corp., Liangyungang, China) for 24 h at 37°C. Cell density was measured using the CCK-8 assay according to the manufacturer's instructions. The absorbance of each well was determined at a wavelength of 450 nm using a microplate reader (Thermo Electron Corp., Shanghai, China). The inhibition rate was calculated as follows: Inhibition rate (%)=[1-(T-B)/(U-B)]x100%; where T is the treated cell absorbance, U is the untreated cell absorbance and B is the background absorbance when neither drug nor CCK-8 was added. All experiments were repeated at least three times independently.

Combination index (CI) analysis. To evaluate whether the antitumor effects of niclosamide combined with DDP were synergistic, additive or antagonistic, combination index (CI) value for drug synergy was calculated using the CompuSyn software (Version 2.1, ComboSyn, Inc., Paramus, NJ, USA) as previously described (14). Using data obtained from CCK-8 assays and CompuSyn software, the dose-effect curves for single agents and their combinations were generated, and the CI values for each dose and the corresponding effect level, referred to as the fraction affected (Fa; the fraction of cells inhibited following drug exposure, for example 0.5 when cell growth is inhibited by 50%), were calculated. CI values <1 indicated a synergistic effect, values equal to 1 indicated an additive effect and values >1 indicated an antagonistic effect. Then, to provide a visual illustration of drug interactions, the Fa-CI plot was constructed by simulating CI values over a range of Fa levels from 0.1 to 0.95 (18,19).

Analysis of apoptosis by Annexin V/Propidium iodide (PI) staining. Apoptosis was assessed by Annexin V/PI detection as described previously (20). The A549/DDP cells were plated at a density of 1x10⁵ cells per well in six-well plates. The next day, cells were treated with DDP (5 µg/ml), niclosamide (1 µM) or cisplatin (5 µg/ml) combined with niclosamide (1 µM) for 36h. The cells were harvested, and washed three times with phosphate-buffered saline (PBS) at 4°C. Cells were then incubated with 5 µl Annexin V-fluorescein isothiocyanate for 3 min and with 20 ng/ml PI in the dark for 15 min. The suspension was then analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA). All data were collected and analyzed by FACSDiva version 6.1.3 (BD Biosciences). The experiments were repeated three times independently and the results were presented as the mean ± standard deviation.

Western blot analysis. Subsequent to treatments, the cells were collected and lysed. Lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, sodium pyrophosphate, β-glycerophosphate, EDTA, Na₂VO₃ and leupeptin] was purchased from Beyotime Institute of Biotechnology (Shanghai, China). Total protein (~20 µg) was separated on a 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel and transferred to a polyvinylidene fluoride membrane. After blocking with 5% non-fat milk in PBS + 0.1% Tween-20 for 1 h, the membrane was incubated with the appropriate primary antibody: Anti-caspase-3 (#14220; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-LRP (sc-23916; 1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-c-myc (D84C12, 1:1,000; Cell Signaling Technology, Inc.) and anti-β-tubulin (AT819, 1:2,000; Beyotime Institute of Biotechnology) overnight at 4°C. After washing with PBS three times (10 min each), the membrane was incubated with goat anti-rabbit (A0208; 1:2,000; Beyotime Institute of Biotechnology) or anti-mouse (A0216; 1:2,000; Beyotime Institute of Biotechnology) IgG-horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature and washed with PBS three times. The ECL system (Applygen Technologies, Inc., Beijing, China) was used to detect blotting signals according to the manufacturer's instructions. Detection of β-tubulin served as a loading control.

Statistical analysis. Continuous data are expressed as the mean ± standard deviation. For two-group comparison, the Student's t-test method was used. SPSS 13.0 software was used to perform all statistical analyses (SPSS, Inc., Chicago, IL, USA). For more than two-group comparison, one-way ANOVA was used. P<0.05 was considered to indicate a statistically significant difference.
Results

Niclosamide inhibits the growth of A549 and A549/DDP cells. In order to confirm the differential sensitivity of A549 and its derivative cisplatin-resistant cell line, A549/DDP, to DDP, cells were treated with different concentrations of DDP as indicated for 24 h, and cell viability was measured by CCK-8 assay. IC\textsubscript{50} values were calculated using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). The data demonstrated that the IC\textsubscript{50} values of DDP in A549 and A549/DDP cells were 6.81±0.78 and 32.5±0.21 µg/ml, respectively (Fig. 1). The resistance index of A549/DDP cells to DDP was the IC\textsubscript{50} of A549/DDP cells divided by IC\textsubscript{50} of the A549 cells or 32.5/6.81 µg/ml=4.77. These data demonstrate that the A549/DDP cell line has a certain resistance to DDP, which is suitable for drug resistance study.

The A549 and A549/DDP cells were treated with various concentrations of niclosamide as indicated (0, 0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 µM) for 24 h. Cell viability was measured using CCK-8 assay. The current results demonstrated that niclosamide significantly suppressed cell growth in a dose-dependent manner in A549 and A549/DDP cells (Fig. 2; P<0.05). The IC\textsubscript{50} values after 24 h of niclosamide in the A549 and A549/DDP cells were 2.60±0.21 and 1.15±0.18 µM, respectively. Niclosamide appears to exert a markedly greater inhibitory effect on A549/DDP cells when compared with parental A549 cells.

Niclosamide enhances the inhibitory effect of DDP on A549/DDP cells. To examine whether niclosamide combined with DDP exhibits enhanced antitumor effects in cisplatin-resistant lung cancer, A549/DDP cells were treated with 0.5 or 1 µM niclosamide along with 1.25, 2.5, 5, 10 or 20 µg/ml DDP for 24 h. The niclosamide-treated cells demonstrated increased sensitivity to DDP at all concentrations (Fig. 3; P<0.05). According to the combined index calculated with CompuSyn software, the CI value of DDP in combination with niclosamide was <1, indicating that DDP combined with niclosamide exerts a synergistic effect on A549/DDP cells (Fig. 4).

Niclosamide combined with DDP enhances the apoptosis of A549/DDP cells. Subsequently, the apoptosis of A549/DDP cells after niclosamide (1 µM) and DDP (5 µg/ml) treatment was evaluated using flow cytometry. Apoptotic cells were detected following treatment with 1 µM niclosamide and/or 5 µg/ml DDP for 36 h. Annexin V/PI analysis indicated that the apoptotic ratios of the control group, niclosamide, DDP and combined treatment group in the A549/DDP cells were 8.36±1.05, 11.0±3.18, 16.5±5.25 and 30.36±4.36%, respectively (Fig. 5A and B). The current data demonstrated that niclosamide in combination with DDP significantly enhanced the tumor killing effect by inducing apoptosis. Furthermore, western blotting was used to detect the activation of caspase-3 protein in A549/DDP cells after the same treatment. The cleavage of caspase-3 was observed to be markedly increased in the combined treatment group compared with the mono-treatment group (Fig. 5C). Therefore, the current results indicate that niclosamide combined with DDP may enhance cytotoxic effects by inducing apoptosis in A549/DDP cells.

Niclosamide inhibits the growth of A549 and A549/DDP cells. Cell viability, as assessed by Cell Counting kit-8 assay, was determined 24 h after exposure of A549 or A549/DDP cells to increasing quantities of DDP. Results represent the mean of triplicate wells and are representative of three independent experiments. *P<0.05 and **P<0.01 vs. control group; DDP, cisplatin; A549, human lung adenocarcinoma cells; A549/DDP, DDP-resistant human lung adenocarcinoma cells.

Niclosamide enhances the inhibitory effect of DDP on A549/DDP cells. A549 or A549/DDP cells were treated with increasing concentrations of niclosamide as indicated for 24 h, and examined by Cell Counting kit-8 assay. Viability was normalized to 100% at time zero. Results represent the mean of triplicate wells and are representative of three independent experiments. *P<0.05 and **P<0.01 vs. control group; A549 vs. A549/DDP group. DDP, cisplatin; A549, human lung adenocarcinoma cells; A549/DDP, DDP-resistant human lung adenocarcinoma cells.

Niclosamide combined with DDP enhances the apoptosis of A549/DDP cells. Proliferation inhibition was determined by Cell Counting kit-8 assays 24 h after exposure to a range of concentrations of DDP and 0.5 or 1.0 µmol/l niclosamide plus a range of concentrations of DDP. The inhibition rate of the combined treatment increased markedly at 24 h compared with DDP alone. Results represent the mean of three experiments performed in triplicate. *P<0.05 and **P<0.01 vs. DDP alone group. DDP, cisplatin; A549, human lung adenocarcinoma cells; A549/DDP, DDP-resistant human lung adenocarcinoma cells.
Niclosamide sensitizes A549/DDP cells to DDP by downregulating LRP and c-myc. To further document the underlying mechanisms by which niclosamide enhanced the inhibitory effect of DDP in A549/DDP cells, western blotting was used to detect the impact of niclosamide on DDP-resistant associated proteins. Initially, the basic expression levels of LRP and c-myc proteins were evaluated in A549 and A549/DDP cells. The expression levels of LRP and c-myc proteins in A549/DDP cells were significantly higher than those of the A549 cells (Fig. 6A). Subsequently, the changes of LRP and c-myc protein expression levels were investigated after treatment with niclosamide and/or DDP in A549/DDP cells. Following treatment with 1.0 μM niclosamide alone, A549/DDP cells demonstrated downregulation of LRP and c-myc protein expression levels, while DDP alone exerted no effect on LRP and c-myc protein expression levels. However, upon the combination treatment of niclosamide and DDP, the expression levels of the two proteins were significantly decreased compared with the controls (Fig. 6B). Due to the roles of LRP and c-myc protein on DDP resistance, it was inferred that niclosamide may enhance the
cytotoxic effect of DDP on A549/DDP cells by downregulating the expression level of c-myc protein.

Discussion

DDP treatment often results in the development of chemoresistance, leading to therapeutic failure (21). Establishing drugs that may overcome DDP resistance is a promising strategy for improving the therapeutic effects of lung cancer treatment. However, drug development, from the initial lead discovery to the final medication, is an expensive and lengthy process (22). By contrast, identifying novel indications for old drugs is considerably faster and more economical than inventing a novel drug altogether, as existing drugs have known pharmacokinetics and safety profiles, and have often been approved for human use (23). In the present study, niclosamide markedly suppressed the proliferation of cisplatin-resistant human A549/DDP lung cancer cells in vitro (Fig. 2). Furthermore, the current study demonstrated that niclosamide in combination with DDP resulted in a synergistic effect in A549/DDP cells (Fig. 3).

Previous studies have reported that niclosamide exhibited synergistic effects when combined with chemotherapeutic agents, oxaliplatin (24), cytarabine, etoposide, daunorubicin and temozolomide (25), and DDP (17). Additionally, niclosamide reversed the resistance of human head and neck cancer cells, and non-small cell lung cancer cells to erlotinib (16,26). Similarly, Liu et al (17) identified that niclosamide alone or in combination with DDP significantly inhibited MDA-MB-231/CS and MDA-MB-231/CR cell proliferation in vitro. Therefore, niclosamide reduces the proliferation of cisplatin-resistant lung cancer cells, indicating that niclosamide may serve as a novel therapeutic strategy, either alone or in combination with DDP, for lung cancer treatment, particularly those resistant to DDP.

The development of DDP resistance arises due to changes in the biochemical pharmacology of DDP. To elucidate whether niclosamide enhances the antitumor effect in A549/DDP cells, the expression levels of LRP and c-myc proteins were examined, and found to be associated with DDP-resistance. Notably, LRP and c-myc were significantly overexpressed in A549/DDP cells compared with A549 cells, and niclosamide reduced the expression levels of LRP and c-myc proteins (Fig. 6). LRP is the predominant human vault protein (27). It reduces the drug concentration in the nucleus and decreases the drug effect on DNA targets (28). A previous study demonstrated that vaults, including LRP, are overexpressed in multidrug-resistant cancer cell lines (29). Consistently, the level of LRP expression is significantly higher in cisplatin-resistant A549/DDP cells than that in parental A549 cells. Furthermore, clinical studies have reported that LRP expression levels predict drug resistance and poor outcome in various types of cancer (30,31). LRP was identified as an independent prognostic factor for overall survival in advanced NSCLC treated with DDP-based chemotherapy (32-34).

C-myc is an important proto-oncogene associated with tumor occurrence and development; its abnormal expression is significant in promoting cell division and proliferation (35). C-myc has been demonstrated to function in numerous cellular processes, including cell proliferation, differentiation and transformation. In addition, c-myc influences cellular sensitivity to DDP (36). Analysis of a panel of ovarian cancer cell lines demonstrated that c-myc protein expression levels were higher in cisplatin-resistant cells when compared with their cisplatin-resistant counterparts. Furthermore, silencing of c-myc by siRNA significantly reduced the tumor growth of cisplatin-resistant cell xenografts (37). Xie et al (38) demonstrated that c-myc was important in regulating DDP resistance in A549/DDP lung cancer cells. Consequently, the current data indicates that niclosamide may enhance the antitumor effect of DDP via suppression of LRP and c-myc proteins, and niclosamide may be a potentially useful therapeutic agent for the treatment of cisplatin-resistant human lung cancer.

On the basis of our findings, combined treatment with niclosamide and DDP may represent a novel and effective strategy for treatment of NSCLC, including for those patients who have already developed resistance to platinum-based therapy. An in vivo animal model would assist in further investigating the efficacy prior to clinical assessment.

Acknowledgements

The present study was supported by funding from the National Natural Science Foundation of China (grant no. 81201736), Natural Science Foundation of Guangdong Province, China (grant no. 2015A030310460), The Research Fund of Guangdong Medical University (grant no. 2X14031).
References

1. Jamal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 224-249, 2009.
2. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Leven MG, Kerr K, Popat S, Reck M, Senan S, et al: Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27 (suppl 5): v1-227, 2016.
3. Crino L, Weder W, van Meerbeeck J and Felip E: ESMO Working Group: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 (suppl 5): v1-156, 2018.
4. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9: 154-162, 2014.
5. Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MJ and Reck M: A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 14: 215-223, 2013.
6. Fennell DA, Summers Y, Cadranel J, Benpala T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Gruï C and Ferry D: Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 44: 42-50, 2016.
7. Lo Iacono M, Monica V, Vavalà T, Gisabella M, Saviozzi S, Bracco E, Novello S, Papotti M and Scaglioni GV: ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/AKT2 pathway. Int J Cancer 136: 2598-2609, 2015.
8. Huang F, Duan S, Tsai Y, Keng PC, Chen Y, Lee SO and Chen Y: Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. Cancer Sci 107: 746-754, 2016.
9. Al-Hadiya BM: Niclosamide: Comprehensive profile. Profiles Drug Subst Expl Relat Methodol 33: 199-205, 2005.
10. Al-Ghurair F, Semin KD and Alka rawiya HM: Niclosamide as an anti-obesity drug: An experimental study. Eat Weight Disord 22: 339-344, 2017.
11. Chowdhury MK, Turner N, Bentley NL, Das A, Wu LE, Richani D, Bustamante S, Gilchrist RB, Morris MJ, Shepherd PR and Smith GC: Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice. Implications for glucose metabolism improvements in type 2 diabetes. Sci Rep 7: 40159, 2017.
12. Huang L, Yang M, Yuan Y, Li X and Kuang E: Niclosamide inhibits IL-6 induction of Epstein-Barr virus by disrupting mTOR activation. Antiviral Res 138: 68-78, 2017.
13. Wang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, Lai ZZ, Kuo SC and Ho YF: Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. Antiviral Res 135: 81-90, 2016.
14. Morin F, Kavian N, Nicco C, Cerles O, Chéreau C and Batteux F: Niclosamide prevents systemic sclerosis in a reactive oxygen species-induced mouse model. J Immunol 197: 3018-3028, 2016.
15. Li Y, Li PK, Roberts MJ, Arend RC, Samant RS and Buchsbaum DJ: Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett 349: 8-14, 2014.
16. Li R, Hu Z, Sun SY, Chen ZG, Owo nikoko TK, Sica GL, Ramalingam SS, Curran WJ, Khuri FR and Deng X: Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther 12: 2900-2012, 2013.
17. Liu J, Chen X, Ward T, Pegram M and Shen K: Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumour Biol 37: 9825-9835, 2016.
18. Klimaszewska-Waszowska A, Osada T, Chen M, Yang XY, Spasovic I, Vandeusen JB, Harel-Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis 5: e1227, e201, 2014.
19. Tessari M, Pilla M, Andredoi M, Hutcheson DM and Heidbreder CA: Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 499: 121-133, 2004.
20. Chen CR and Sullivan DJ Jr: New uses for old drugs. Nature 448: 645-646, 2007.
21. Osada T, Chen M, Yang XY, Spasovic I, Vandeusen JB, Harel-Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis 5: e1227, e201, 2014.
22. Lo Iacono M, Monica V, Vavalà T, Gisabella M, Saviozzi S, Bracco E, Novello S, Papotti M and Scaglioni GV: ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/AKT2 pathway. Int J Cancer 136: 2598-2609, 2015.
23. Prasad PK, Zhou Y, Bhatia A, Ho PL, Schiller DJ and Copeland EM III: Mammalian target of rapamycin (mTOR) activation. Antiviral Res 138: 68-78, 2017.
24. Zhang W, Zhou H, Yu Y, Li J, Li H, Jiang D, Chen Z, Yang D, Xu Z and Yu Z: Combination of gambogenic acid with cisplatin enhances the anti-tumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Onco Targets Ther 9: 3359-3368, 2016.
25. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis 5: e1227, e201, 2014.
26. Wang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, Lai ZZ, Kuo SC and Ho YF: Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. Antiviral Res 135: 81-90, 2016.